Prognostic role of Tif1γ expression and circulating tumor cells in patients with breast cancer
- Authors:
- Fengfeng Cai
- Lu Cai
- Zhuchao Zhou
- Xin Pan
- Minghong Wang
- Su Chen
- Manuel Antonio Falar Luis
- Chunmei Cen
- Ewelina Biskup
-
Affiliations: Department of Breast Surgery, Yangpu Hospital, Tongji University School of Medicine, Shanghai 200090, P.R. China, Department of General Surgery, Huashan Hospital, Fudan University, School of Medicine, Shanghai 200041, P.R. China, Department of Central Laboratory, Yangpu Hospital, Tongji University School of Medicine, Shanghai 200090, P.R. China, Department of Cardiology, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai 200438, P.R. China, Department of Molecular and Cellular Biology, School of Forensic Sciences, Xi'an Jiao Tong University Health Science Center, Xi'an, Shanxi 710061, P.R. China, Department of Basic Medical Sciences, Shanghai University of Medicine and Health Sciences, Shanghai 201318, P.R. China - Published online on: March 14, 2019 https://doi.org/10.3892/mmr.2019.10033
- Pages: 3685-3695
-
Copyright: © Cai et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
 |
 |
 |
 |
|
Herquel B, Ouararhni K and Davidson I: The TIF1α-related TRIM cofactors couple chromatin modifications to transcriptional regulation, signaling and tumor suppression. Transcription. 2:231–236. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Venturini L, You J, Stadler M, Galien R, Lallemand V, Koken MH, Mattei MG, Ganser A, Chambon P, Losson R and de Thé H: TIF1gamma, a novel member of the transcriptional intermediary factor 1 family. Oncogene. 18:1209–1217. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Hatakeyama S: TRIM proteins and cancer. Nat Rev Cancer. 11:792–804. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Herquel B, Ouararhni K, Khetchoumian K, Ignat M, Teletin M, Mark M, Béchade G, Van Dorsselaer A, Sanglier-Cianférani S, Hamiche A, et al: Transcription cofactors TRIM24, TRIM28, and TRIM33 associate to form regulatory complexes that suppress murine hepatocellular carcinoma. Proc Natl Acad Sci USA. 108:8212–8217. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Chen T and Dent SY: Chromatin modifiers and remodellers: Regulators of cellular differentiation. Nat Rev Genet. 15:93–106. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Xi Q, Wang Z, Zaromytidou AI, Zhang XH, Chow-Tsang LF, Liu JX, Kim H, Barlas A, Manova-Todorova K, Kaartinen V, et al: A poised chromatin platform for TGF-β access to master regulators. Cell. 147:1511–1524. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Massagué J and Xi Q: TGF-β control of stem cell differentiation genes. FEBS Lett. 586:1953–1958. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Heldin CH and Moustakas A: A new twist in Smad signaling. Dev Cell. 10:685–686. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Moustakas A and Heldin CH: The regulation of TGFbeta signal transduction. Development. 136:3699–3714. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Heldin CH and Moustakas A: Role of Smads in TGFβ signaling. Cell Tissue Res. 347:21–36. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Attisano L and Lee-Hoeflich ST: The Smads. Genome Biol. 2:REVIEWS30102001. View Article : Google Scholar : PubMed/NCBI | |
|
Smith AP, Verrecchia A, Fagà G, Doni M, Perna D, Martinato F, Guccione E and Amati B: A positive role for Myc in TGFbeta-induced Snail transcription and epithelial-to-mesenchymal transition. Oncogene. 28:422–430. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Padgett RW: TGFbeta signaling pathways and human diseases. Cancer Metastasis Rev. 18:247–259. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Dupont S, Zacchigna L, Cordenonsi M, Soligo S, Adorno M, Rugge M and Piccolo S: Germ-layer specification and control of cell growth by ectodermin, a Smad4 ubiquitin ligase. Cell. 121:87–99. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Morsut L, Yan KP, Enzo E, Aragona M, Soligo SM, Wendling O, Mark M, Khetchoumian K, Bressan G, Chambon P, et al: Negative control of Smad activity by ectodermin/Tif1gamma patterns the mammalian embryo. Development. 137:2571–2578. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Agricola E, Randall RA, Gaarenstroom T, Dupont S and Hill CS: Recruitment of TIF1g to Chromatin via Its PHD finger-bromodomain activates its ubiquitin ligase and transcriptional repressor activities. Mol Cell. 43:85–96. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Kusy S, Gault N, Ferri F, Lewandowski D, Barroca V, Jaracz-Ros A, Losson R and Romeo PH: Adult hematopoiesis is regulated by TIF1γ, a repressor of TAL1 and PU.1 transcriptional activity. Cell Stem Cell. 8:412–425. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Bai RY, Koester C, Ouyang T, Hahn SA, Hammerschmidt M, Peschel C and Duyster J: SMIF, a Smad4-interacting protein that functions as a co-activator in TGFbeta signalling. Nat Cell Biol. 4:181–190. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
He W, Dorn DC, Erdjument-Bromage H, Tempst P, Moore MA and Massagué J: Hematopoiesis controlled by distinct TIF1gamma and Smad4 Branches of the TGFbeta Pathway. Cell. 125:929–941. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Aucagne R, Droin N, Paggetti J, Lagrange B, Largeot A, Hammann A, Bataille A, Martin L, Yan KP, Fenaux P, et al: Transcription intermediary factor 1γ is a tumor suppressor in mouse and human chronic myelomonocytic leukemia. J Clin Invest. 121:2361–2370. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Emanuel PD: Juvenile myelomonocytic leukemia and chronic myelomonocytic leukemia. Leukemia. 22:1335–1342. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Quéré R, Saint-Paul L, Carmignac V, Martin RZ, Chrétien ML, Largeot A, Hammann A, Pais de Barros JP, Bastie JN and Delva L: Tif1γ regulates the TGF-β1 receptor and promotes physiological aging of hematopoietic stem cells. Proc Natl Acad Sci USA. 111:10592–10597. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Lindley LE and Briegel KJ: Generation of mice with a conditional Lbh null allele. Genesis. 51:491–497. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Zhou Y, You MJ, Young KH, Lin P, Lu G, Medeiros LJ and Bueso-Ramos CE: Advances in the molecular pathobiology of B-lymphoblastic leukemia. Hum Pathol. 43:1347–1362. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Wang E, Kawaoka S, Roe JS, Shi J, Hohmann AF, Xu Y, Bhagwat AS, Suzuki Y and Kinney JB: The transcriptional cofactor TRIM33 prevents apoptosis in B lymphoblastic leukemia by deactivating a single enhancer. Elife. 4:e063772015. View Article : Google Scholar : PubMed/NCBI | |
|
Yuan N, Song L, Zhang S, Lin W, Cao Y, Xu F, Fang Y, Wang Z, Zhang H, Li X, et al: Bafilomycin A1 targets both autophagy and apoptosis pathways in pediatric B-cell acute lymphoblastic leukemia. Haematologica. 100:345–356. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Jain S, Singhal S, Francis F, Hajdu C, Wang JH, Suriawinata A, Wang YQ, Zhang M, Weinshel EH, Francois F, et al: Association of overexpression of TIF1γ with colorectal carcinogenesis and advanced colorectal adenocarcinoma. World J Gastroenterol. 17:3994–4000. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Jain S, Yu M, Singhal S, Francis F, Hajdu C, Suriawinata S, Zhang M, Aladhamy N, Chiriboga L, Pan R, et al: Overexpression of transcription intermediary factor 1 γ (TIF1γ) is an early event in colorectal carcinogenesis and inversely related to Smad4 inactivation in colorectal carcinoma. Lab Investig. 90:149A2010. | |
|
Fearon ER and Vogelstein B: A genetic model for colorectal tumorigenesis. Cell. 61:759–767. 1990. View Article : Google Scholar : PubMed/NCBI | |
|
Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics: 2011. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, Forman D and Bray F: Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012. Eur J Cancer. 49:1374–1403. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Siegel RL, Miller KD and Jemal A: Cancer statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Sikov WM, Berry DA, Perou CM, Singh B, Cirrincione CT, Tolaney SM, Kuzma CS, Pluard TJ, Somlo G, Port RT, et al: Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance). J Clin Oncol. 33:13–21. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Desantis C, Ma J, Bryan L and Jemal A: Breast cancer statistics, 2013. CA Cancer J Clin. 64:52–62. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Sharma P, Stecklein SR, Kimler BF, Sethi G, Petroff BK, Phillips TA, Tawfik OW, Godwin AK and Jensen RA: The prognostic value of BRCA1 promoter methylation in early stage triple negative breast cancer. J Cancer Ther Res. 3:1–11. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Müller HM, Fiegl H, Widschwendter A and Widschwendter M: Prognostic DNA methylation marker in serum of cancer patients. Annals of the New York Academy of Sciences. pp44–49. 2004. View Article : Google Scholar | |
|
Duffy MJ: Serum tumor markers in breast cancer: Are they of clinical value? Clin Chem. 52:345–351. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Cai FF, Kohler C, Zhang B, Wang MH, Chen WJ and Zhong XY: Epigenetic therapy for breast cancer. Int J Mol Sci. 12:4465–4487. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Sharma S, Kelly TK and Jones PA: Epigenetics in cancer. Carcinogenesis. 31:27–36. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Kumar R: Breast cancer tumor markers. J Solid Tumors. 2:432012. View Article : Google Scholar | |
|
Payne SJ, Bowen RL, Jones JL and Wells CA: Predictive markers in breast cancer-the present. Histopathology. 52:82–90. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Wakefield LM and Roberts AB: TGF-beta signaling: Positive and negative effects on tumorigenesis. Curr Opin Genet Dev. 12:22–29. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Giampieri S, Manning C, Hooper S, Jones L, Hill CS and Sahai E: Localized and reversible TGFbeta signalling switches breast cancer cells from cohesive to single cell motility. Nat Cell Biol. 11:1287–1296. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Ikushima H and Miyazono K: TGFbeta signalling: A complex web in cancer progression. Nat Rev Cancer. 10:415–424. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Faure E, Heisterkamp N, Groffen J and Kaartinen V: Differential expression of TGF-beta isoforms during postlactational mammary gland involution. Cell Tissue Res. 300:89–95. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Nguyen AV and Pollard JW: Transforming growth factor beta3 induces cell death during the first stage of mammary gland involution. Development. 127:3107–3118. 2000.PubMed/NCBI | |
|
Li M, Liu X, Robinson G, Bar-Peled U, Wagner KU, Young WS, Hennighausen L and Furth PA: Mammary-derived signals activate programmed cell death during the first stage of mammary gland involution. Proc Natl Acad Sci USA. 94:3425–3430. 1997. View Article : Google Scholar : PubMed/NCBI | |
|
Bierie B, Gorska AE, Stover DG and Moses HL: TGF-beta promotes cell death and suppresses lactation during the second stage of mammary involution. J Cell Physiol. 219:57–68. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Panis C, Herrera AC, Victorino VJ, Aranome AM and Cecchini R: Screening of circulating TGF-beta levels and its clinicopathological significance in human breast cancer. Anticancer Res. 33:737–742. 2013.PubMed/NCBI | |
|
Paiva CE, Drigo SA, Rosa FE, Moraes Neto FA, Caldeira JR, Soares FA, Domingues MA and Rogatto SR: Absence of transforming growth factor-beta type II receptor is associated with poorer prognosis in HER2-negative breast tumours. Ann Oncol. 21:734–740. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Richardsen E, Uglehus RD, Johnsen SH and Busund LT: Immunohistochemical expression of epithelial and stromal immunomodulatory signalling molecules is a prognostic indicator in breast cancer. BMC Res Notes. 5:1102012. View Article : Google Scholar : PubMed/NCBI | |
|
Desruisseau S, Palmari J, Giusti C, Romain S, Martin PM and Berthois Y: Determination of TGFbeta1 protein level in human primary breast cancers and its relationship with survival. Br J Cancer. 94:239–246. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Koumoundourou D, Kassimatis T, Zolota V, Tzorakoeleftherakis E, Ravazoula P, Vassiliou V, Kardamakis D and Varakis J: Prognostic significance of TGFbeta-1 and pSmad2/3 in breast cancer patients with T1-2,N0 tumours. Anticancer Res. 27:2613–2620. 2007.PubMed/NCBI | |
|
Vincent DF, Yan KP, Treilleux I, Gay F, Arfi V, Kaniewsky B, Marie JC, Lepinasse F, Martel S, Goddard-Leon S, et al: Inactivation of TIF1gamma cooperates with Kras to induce cystic tumors of the pancreas. PLoS Genet. 5:e10005752009. View Article : Google Scholar : PubMed/NCBI | |
|
Fattet L, Ay AS, Bonneau B, Jallades L, Mikaelian I, Treilleux I, Gillet G, Hesling C and Rimokh R: TIF1γ requires sumoylation to exert its repressive activity on TGFβ signaling. J Cell Sci. 126:3713–3123. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Mascle XH, Germain-Desprez D, Huynh P, Estephan P and Aubry M: Sumoylation of the transcriptional intermediary factor 1beta (TIF1beta), the Co-repressor of the KRAB multifinger proteins, is required for its transcriptional activity and is modulated by the KRAB domain. J Biol Chem. 282:10190–10202. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Kretzschmar M, Doody J, Timokhina I and Massagué J: A mechanism of repression of TGFbeta/Smad signaling by oncogenic Ras. Genes Dev. 13:804–816. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Wang L, Yang H, Lei Z, Zhao J, Chen Y, Chen P, Li C, Zeng Y, Liu Z, Liu X and Zhang HT: Repression of TIF1γ by SOX2 promotes TGF-β-induced epithelial-mesenchymal transition in non-small-cell lung cancer. Oncogene. 35:867–877. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Mikaelian I, Malek M, Gadet R, Viallet J, Garcia A, Girard-Gagnepain A, Hesling C, Gillet G, Gonzalo P, Rimokh R and Billaud M: Genetic and pharmacologic inhibition of mTORC1 promotes EMT by a TGF-β-independent mechanism. Cancer Res. 73:6621–6631. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Hesling C, Fattet L, Teyre G, Jury D, Gonzalo P, Lopez J, Vanbelle C, Morel AP, Gillet G, Mikaelian I and Rimokh R: Antagonistic regulation of EMT by TIF1γ and Smad4 in mammary epithelial cells. EMBO Rep. 12:665–672. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Hesling C, Lopez J, Fattet L, Gonzalo P, Treilleux I, Blanchard D, Losson R, Goffin V, Pigat N, Puisieux A, et al: Tif1γ is essential for the terminal differentiation of mammary alveolar epithelial cells and for lactation through SMAD4 inhibition. Development. 140:167–175. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Kassem L, Deygas M, Fattet L, Lopez J, Goulvent T, Lavergne E, Chabaud S, Carrabin N, Chopin N, Bachelot T, et al: TIF1γ interferes with TGFβ1/SMAD4 signaling to promote poor outcome in operable breast cancer patients. BMC Cancer. 15:4532015. View Article : Google Scholar : PubMed/NCBI | |
|
Kim MY, Oskarsson T, Acharyya S, Nguyen DX, Zhang XH, Norton L and Massagué J: Tumor self-seeding by circulating cancer cells. Cell. 139:1315–1326. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Li P, Mao Z, Peng Z, Zhou L, Chen Y, Huang PH, Truica CI, Drabick JJ, El-Deiry WS, Dao M, et al: Acoustic separation of circulating tumor cells. Proc Natl Acad Sci USA. 112:4970–4975. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Dive C and Brady G: SnapShot: Circulating tumor cells. Cell. 168:P742–P742.e1. 2017. View Article : Google Scholar | |
|
Dawson SJ, Tsui DW, Murtaza M, Biggs H, Rueda OM, Chin SF, Dunning MJ, Gale D, Forshew T, Mahler-Araujo B, et al: Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med. 368:1199–1209. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Scully OJ, Bay BH, Yip G and Yu Y: Breast cancer metastasis. Cancer Genomics Proteomics. 9:311–320. 2012.PubMed/NCBI | |
|
Kuo AH and Clarke MF: Identifying the metastatic seeds of breast cancer. Nat Biotechnol. 31:504–505. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, Reuben JM, Doyle GV, Allard WJ, Terstappen LWMM and Hayes DF: Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 351:781–791. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Giuliano M, Giordano A, Jackson S, Hess KR, de Giorgi U, Mego M, Handy BC, Ueno NT, Alvarez RH, De Laurentiis M, et al: Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment. Breast Cancer Res. 13:R672011. View Article : Google Scholar : PubMed/NCBI | |
|
Pierga JY, Bidard FC, Mathiot C, Brain E, Delaloge S, Giachetti S, de Cremoux P, Salmon R, Vincent-Salomon A and Marty M: Circulating tumor cell detection predicts early metastatic relapse after neoadjuvant chemotherapy in large operable and locally advanced breast cancer in a phase II randomized trial. Clin Cancer Res. 14:7004–7010. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Bidard FC, Proudhon C and Pierga JY: Circulating tumor cells in breast cancer. Mol Oncol. 10:418–430. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Pan X, Zeng SL, Yu D, Liang XL, Ji C, Pan B, Cai J, Wang Y, Min Y, Fang W and Liao WQ: Variable domain of the heavy chain of heavy-chain antibody of the Rv0733 antigen of mycobacterium tuberculosis panned and identified from a nonimmune llama VHH phage display library. Int J Clin Exp Pathol. 9:2869–2878. 2016. | |
|
Lin XY, Cai FF, Wang MH, Pan X, Wang F, Cai L, Cui RR, Chen S and Ewelina B: Mammalian sterile 20-like kinase 1 expression and its prognostic significance in patients with breast cancer. Oncology Lett. 14:5457–5463. 2017. | |
|
Chen B, Le W, Wang Y, Li Z, Wang D, Ren L, Lin L, Cui S, Hu JJ, Hu Y, et al: Targeting negative surface charges of cancer cells by multifunctional nanoprobes. Theranostics. 6:1887–1898. 2018. View Article : Google Scholar | |
|
Banin Hirata BK, Oda JM, Losi Guembarovski R, Ariza CB, de Oliveira CE and Watanabe MA: Molecular markers for breast cancer: Prediction on tumor behavior. Dis Markers. 2014:5131582014. View Article : Google Scholar : PubMed/NCBI | |
|
Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ, Speed D, Lynch AG, Samarajiwa S, Yuan Y, et al: The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature. 486:346–352. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Hah N, Danko CG, Core L, Waterfall JJ, Siepel A, Lis JT and Kraus WL: A rapid, extensive, and transient transcriptional response to estrogen signaling in breast cancer cells. Cell. 145:622–634. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Xiong R, Zhao J, Gutgesell LM, Wang Y, Lee S, Karumudi B, Zhao H, Lu Y, Tonetti DA and Thatcher GR: Novel selective estrogen receptor downregulators (SERDs) developed against treatment-resistant breast cancer. J Med Chem. 60:1325–1342. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Reis-Filho JS and Pusztai L: Gene expression profiling in breast cancer: Classification, prognostication, and prediction. Lancet. 378:1812–1823. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Assi HA, Khoury KE, Dbouk H, Khalil LE, Mouhieddine TH and El Saghir NS: Epidemiology and prognosis of breast cancer in young women. J Thorac Dis. 5 (Suppl 1):S2–S8. 2013.PubMed/NCBI | |
|
Hefti MM, Hu R, Knoblauch NW, Collins LC, Haibe-Kains B, Tamimi RM and Beck AH: Estrogen receptor negative/progesterone receptor positive breast cancer is not a reproducible subtype. Breast Cancer Res. 15:R682013. View Article : Google Scholar : PubMed/NCBI | |
|
Cancer Research UK: Breast cancer incidence statistics. Cancer Res UK. 2012. | |
|
Ban KA and Godellas CV: Epidemiology of breast cancer. Surg Oncol Clin N Am. 23:409–422. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Cianfrocca M and Goldstein LJ: Prognostic and predictive factors in early-stage breast cancer. Oncologist. 9:606–616. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: GLOBOCAN 2012 v1.0, Cancer incidence and mortality worldwide: IARC CancerBase. No. 11 [Internet]. Lyon: Fr Int Agency Res Cancer. 11. http://globocan.iarc.f2013 | |
|
Yoneda A, Lendorf ME, Couchman JR and Multhaupt HA: Breast and ovarian cancers: A survey and possible roles for the cell surface heparan sulfate proteoglycans. J Histochem Cytochem. 60:9–21. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Esteva FJ and Hortobagyi GN: Prognostic molecular markers in early breast cancer. Breast Cancer Res. 6:109–118. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Prat A, Parker JS, Karginova O, Fan C, Livasy C, Herschkowitz JI, He X and Perou CM: Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res. 12:R682010. View Article : Google Scholar : PubMed/NCBI | |
|
Payne SJL, Bowen RL, Jones JL and Wells CA: Predictive markers in breast cancer-the present. Histopathology. 52:82–90. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Andrieux G, Fattet L, Le Borgne M, Rimokh R and Théret N: Dynamic regulation of Tgf-B signaling by Tif1γ: A computational approach. PLoS One. 7:e337612012. View Article : Google Scholar : PubMed/NCBI |
